Hyperparathyroidism
A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
Subtype terms (2)
More specific conditions that are subtypes of Hyperparathyroidism in the MeSH hierarchy.
- Hyperparathyroidism, Primary
17 drugs (11 approved, 6 experimental)
- Hyperparathyroidism, Secondary
29 drugs (18 approved, 11 experimental)
Drugs by status
Phase 3 trials (1)
Phase 2 trials (9)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (59)
- Abbott
- AbbVie
- Amgen
- Merck
- Genzyme
- Effice Servicios Para la Investigacion S.L.
- Kyowa Hakko Kirin
- Nabi Biopharmaceuticals
- Fundación Senefro
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Hospital Universitari de Bellvitge
- Aarhus University
- Anhui Medical University
- Chulalongkorn University
- Cornell University
- Duke University
- Emory University
- Henry Ford Health System
- Institut National de la Santé Et de la Recherche Médicale, France
- Istituto Auxologico Italiano
- Mahidol University
- Nanjing Medical University
- Nanjing University
- Northwestern University
- Papageorgiou General Hospital
- Seoul National University
- Wuhan University
- Capital Medical University
- Chinese University of Hong Kong
- +29 more
Organization Involved with Phase 3 Indications (13)
- Sanofi
- GlaxoSmithKline
- Sanwa Kagaku Kenkyusho Co., Ltd.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- United States Army
- Istituto Giannina Gaslini
- Harvard University
- Thomas Jefferson University
- Yale University
- Aalborg University
- University of California, San Francisco
- Phelps, Kenneth R., M.D.
- University of Genoa
Organization Involved with Phase 2 Indications (14)
- KAI Pharmaceuticals
- Astellas
- Deltanoid Pharmaceuticals
- British Columbia Cancer Agency
- University of Milan
- University of British Columbia
- University of California, Los Angeles
- Sun Yat-Sen University
- Mario Negri Institute
- First People's Hospital Fo Shan City
- People's Hospital Shun De City
- Shantou University
- University of Caen-Normandie
- People's Hospital of Zhongshan
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (24)
- Roxane Laboratories
- Tzu Chi University
- Indiana University
- Kumamoto University
- Loma Linda University
- Min-Sheng General Hospital
- ProMedica Health System
- Siriraj Hospital
- University of Maryland
- Wroclaw Medical University
- Mayo Clinic
- Saarland University
- Taipei Medical University
- University of Copenhagen
- University of Ferrara
- University of Toledo
- National Taiwan University
- Karolinska Institute
- Government of China
- Bio-Kinetic Clinical Applications
- En Chu Kong Hospital
- Yeshiva University
- Government of Poland
- Government of Thailand